BLOC1S4 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 cell line, featuring targeted disruption of the BLOC1S4 gene. This population provides a heterogeneous loss-of-function model for studying BLOC1S4-dependent processes. The CRISPR/Cas9 system was employed to introduce gene disruptions, generating a pool of cells with varied edits that collectively ablate functional protein expression. This polyclonal format avoids clonal artifacts and enables robust analysis of BLOC1S4 deficiency in a lung adenocarcinoma background.
The parental A-549 cell line was established from lung adenocarcinoma tissue of a 58-year-old Caucasian male. These cells display adherent epithelial morphology and are widely utilized as a model for human lung adenocarcinoma. A-549 cells retain key oncogenic signaling features and are employed in cancer biology, drug development, and toxicology studies. Their well-characterized growth properties and responsiveness to therapeutic agents make them a valuable platform for genetic manipulation and functional genomics.
BLOC1S4 encodes a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1). As a core component, BLOC1S4 interacts with other BLOC-1 subunits (BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S5, BLOC1S6) and facilitates endosome-to-lysosome-related organelle trafficking. It is essential for proper assembly and function of the BLOC-1 complex, which in turn regulates AP-3 complex recruitment to endosomal membranes. Through this network, BLOC1S4 influences the trafficking of cargo such as tyrosinase and PMEL17 to melanosomes, and orchestrates dense granule biogenesis. In non-pigmented cells like A-549, BLOC-1 is implicated in lysosomal positioning and secretion, interacting with Rab32/Rab38, VAMP7, and syntaxin 13 to coordinate organelle dynamics. Disruption of BLOC1S4 thus destabilizes BLOC-1 complex formation, leading to defective lysosomal function and impaired cellular homeostasis.
In A-549 lung adenocarcinoma cells, BLOC1S4 knockout provides a unique model to investigate lysosome-related organelle biology beyond the classical Hermansky-Pudlak syndrome presentations. While mutations in BLOC1S4 are linked to Hermansky-Pudlak syndrome type 8, characterized by oculocutaneous albinism and bleeding diathesis, the role of BLOC-1 in cancer cell lysosomal trafficking is underappreciated. Lysosomes are critical for nutrient sensing, autophagy, and drug sequestration in cancer cells; therefore, BLOC1S4 deficiency may alter sensitivity to lysosomotropic agents and impact tumor cell secretion and migration. This knockout model allows dissection of BLOC-1-dependent pathways in a lung cancer context, bridging rare disease mechanisms with cancer cell biology.
This polyclonal knockout population is suited for a range of experimental applications. It can be employed in Hermansky-Pudlak syndrome disease modeling, endosomal trafficking studies, and lysosome biogenesis research. Representative assays include western blotting and RT-qPCR to confirm BLOC1S4 disruption, immunofluorescence for lysosomal markers such as LAMP1 and LAMP2, LysoTracker staining to assess lysosomal pH and mass, and lysosomal enzyme activity assays. Additionally, migration assays and drug sensitivity screens can reveal functional consequences of BLOC1S4 loss in lung cancer cells. For technical specifications and ordering, contact Ascent Research.
